|
US5007790A
(en)
|
1989-04-11 |
1991-04-16 |
Depomed Systems, Inc. |
Sustained-release oral drug dosage form
|
|
ES2124303T3
(es)
|
1992-03-25 |
1999-02-01 |
Depomed Inc |
Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
|
|
US5582837A
(en)
|
1992-03-25 |
1996-12-10 |
Depomed, Inc. |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
AU3290397A
(en)
|
1996-06-10 |
1998-01-07 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
WO1998055107A1
(en)
|
1997-06-06 |
1998-12-10 |
Depomed, Inc. |
Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
|
|
HK1050135A1
(zh)
|
1999-11-02 |
2003-06-13 |
Depomed, Inc. |
用於促进将药物给予胃的饭後模式药理学诱导
|
|
DE60123384T2
(de)
|
2000-02-04 |
2007-08-02 |
DepoMed, Inc., Menlo Park |
Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
|
|
US6488962B1
(en)
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
|
US6451808B1
(en)
|
2000-10-17 |
2002-09-17 |
Depomed, Inc. |
Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
|
|
MXPA03011096A
(es)
|
2001-05-29 |
2004-12-06 |
Depomed Dev Ltd |
Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
|
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
JP2005508358A
(ja)
|
2001-10-25 |
2005-03-31 |
デポメド・インコーポレイテッド |
胃滞留型ロサルタン投与量を用いる治療方法
|
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
ES2232302B1
(es)
|
2003-11-07 |
2006-08-01 |
Universitat De Les Illes Balears |
Myo-inositol hexafosfato para uso topico.
|
|
ES2288126B2
(es)
|
2006-06-01 |
2009-07-06 |
Universitat De Les Illes Balears |
Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
|
|
ES2332636B1
(es)
|
2008-08-06 |
2011-02-10 |
Universitat De Les Illes Balears |
Composicion de liquido de dialisis.
|
|
BR112014007405B1
(pt)
|
2011-09-29 |
2021-07-13 |
Eth Zurich |
Composto, mio-inositol-pentaquisfosfato-2-peg(400) e forma farmacêutica
|
|
EP2579036A1
(en)
|
2011-10-06 |
2013-04-10 |
Laboratorios Sanifit, S.L. |
Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
|
|
ES2495666B1
(es)
*
|
2013-03-15 |
2015-08-10 |
Laboratoris Sanifit, S.L. |
Uso de derivados con enlaces c-o-p en pacientes con fallo renal
|
|
US9364490B2
(en)
*
|
2013-03-15 |
2016-06-14 |
Laboratoris Sanifit, S.L. |
Use of derivatives containing C—O—P bonds in patients with kidney failure
|
|
JP6893037B2
(ja)
|
2015-12-11 |
2021-06-23 |
エーテーハー・チューリッヒＥＴＨ Ｚｕｒｉｃｈ |
Ｃ．ｄｉｆｆｉｃｉｌｅ感染のための４，６−ジ−（Ｏ−チオホスフェート）−イノシトール−１，２，３，５−テトラ−Ｏ−スルフェート
|
|
DK3386548T3
(da)
|
2015-12-11 |
2021-05-25 |
Eth Zuerich |
Inositol-derivater til anvendelse i patologisk krystallisering
|